Patent 11344552
Litigation summary
Past and pending lawsuits — plaintiffs, defendants, jurisdictions, outcomes, and notable rulings.
Active provider: Google · gemini-2.5-flash
PTAB activity (1)
AIA trial proceedings — IPR, PGR, CBM — filed at the USPTO Patent Trial and Appeal Board against this patent. Sourced directly from the PTAB Trial API.
- IPR2025-01531IPRfiled Sep 12, 2025vs. Apotex Inc.Trial Instituted
Cached for 24 hours. Status strings are sourced verbatim from the PTAB API; the colored badge is our heuristic classification.
Cases on file (3)
Group view →Specific litigation cases in our database that name US patent 11344552. The free-form analysis below may also discuss cases beyond this list.
- CSPC Pharmaceutical Group Limited et al. v. Ipsen Biopharm Ltd.filed Jan 16, 2025IPR2025-00505Patent Trial and Appeal Board (PTAB) of the U.S. Patent and Trademark OfficePending - Instituted
Defendants: Ipsen Biopharm Ltd.
- 1:2024cv04991U.S. District Court for the District of New Jerseyterminated Sep 5, 2025Administratively terminated
Defendants: CONJUPRO BIOTHERAPEUTICS, INC., CSPC PHARMACEUTICAL GROUP LIMITED, and CSPC OUYI PHARMACEUTICAL CO., LTD.
- IPR2025-01531Patent Trial and Appeal Board (PTAB) of the U.S. Patent and Trademark OfficePending - Instituted
Defendants: Ipsen Biopharm Ltd.
Litigation summary
Past and pending lawsuits — plaintiffs, defendants, jurisdictions, outcomes, and notable rulings.
Here's a summary of the known litigation involving US Patent 11,344,552:
1. Inter Partes Review (IPR2025-00505)
- Plaintiff(s): CSPC Pharmaceutical Group Limited, CSPC Ouyi Pharmaceutical Co., Ltd., and Conjupro Biotherapeutics, Inc.
- Defendant(s): Ipsen Biopharm Ltd.
- Jurisdiction: Patent Trial and Appeal Board (PTAB) of the U.S. Patent and Trademark Office.
- Case Number: IPR2025-00505
- Filing Date: January 16, 2025 (or January 17, 2025)
- Current Status: Pending - Instituted. The PTAB decided to institute the IPR on August 14, 2025. Ipsen Biopharm Ltd. filed a request for discretionary denial, but the Acting Director of the USPTO declined to exercise discretionary denial, finding the petitioners' arguments persuasive regarding potential material error during the original patent prosecution.
2. Inter Partes Review (IPR2025-01531)
- Plaintiff(s): Unified Patents
- Defendant(s): Ipsen Biopharm Ltd.
- Jurisdiction: Patent Trial and Appeal Board (PTAB) of the U.S. Patent and Trademark Office.
- Case Number: IPR2025-01531
- Filing Date: No specific filing date is provided in the search results, but it is indicated as "filed" and "Instituted".
- Current Status: Pending - Instituted.
3. District Court Litigation (Consolidated Cases)
- Plaintiff(s): IPSEN BIOPHARMACEUTICALS, INC. and IPSEN BIOPHARM LTD.
- Defendant(s): CONJUPRO BIOTHERAPEUTICS, INC., CSPC PHARMACEUTICAL GROUP LIMITED and CSPC OUYI PHARMACEUTICAL CO., LTD.
- Jurisdiction: U.S. District Court for the District of New Jersey
- Case Numbers: 1:2024cv04991 (filed April 15, 2024) and 1:2025cv13647 (filed July 22, 2025). These cases were consolidated under case number 1:2025cv13647.
- Filing Dates: April 15, 2024 (for 1:2024cv04991) and July 22, 2025 (for 1:2025cv13647)
- Current Status: The case is a civil action for patent infringement, specifically an Abbreviated New Drug Application (ANDA) related case. As of September 5, 2025, the cases were consolidated, and the clerk was directed to administratively terminate case 1:2025cv13647. The docket was last retrieved on September 9, 2025.
Generated 5/24/2026, 6:45:34 AM